 "Alembic Pharma Q3 profit up 30% to Rs 170 cr on robust sales in US")
Alembic Pharmaceuticals Tuesday reported 30 per cent rise in consolidated net profit to Rs 169.83 crore for the quarter ended December 31, 2018 mainly on account of robust sales in the US.
The company had posted a net profit of Rs 130.60 crore in the year-ago period, Alembic Pharma said in a filing to BSE.
Consolidated revenue from operations stood at Rs 1,018.15 crore in the reported quarter as against Rs 840.02 crore in December quarter 2017.
"The growth in the quarter was attributed to a strong performance in the US and international business," MD Pranav Amin said.
The company's formulation as well as active pharmaceutical ingredient (API) facilities were successfully approved by USFDA during the quarter, he added.
The US business grew 42 per cent to Rs 308 crore for the December quarter 2018 as against Rs 218 crore in the year-ago period, it said.
Shares of Alembic Pharma closed at Rs 587.80 per scrip on BSE, down 0.60 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app